{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:02:17Z","timestamp":1740175337373,"version":"3.37.3"},"reference-count":37,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,17]]},"DOI":"10.20945\/2359-3997000000275","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T18:53:01Z","timestamp":1596221581000},"source":"Crossref","is-referenced-by-count":1,"title":["Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?"],"prefix":"10.20945","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1472-7094","authenticated-orcid":false,"given":"Francisco","family":"Bandeira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-451X","authenticated-orcid":false,"given":"Wesdrey","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2617","authenticated-orcid":false,"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"issue":"6","key":"key20200731145257_B1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis","volume":"94","author":"conference","year":"1993","unstructured":"1. Consensus development conference. Consensus Development Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis. Am J Med. 1993;94(6):646-50.","journal-title":"Am J Med"},{"key":"key20200731145257_B2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/BF01622200","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO Report","volume":"4","author":"Compston","year":"1994","unstructured":"2. Compston J. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO Report. Osteoporos Int. 1994;(4):368-81.","journal-title":"Osteoporos Int"},{"issue":"6","key":"key20200731145257_B3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1098-3597(00)90003-6","article-title":"Diagnosis of osteoporosis","volume":"2","author":"Smith","year":"2000","unstructured":"3. Smith J, Shoukri K. Diagnosis of osteoporosis. Clin Cornerstone. 2000;2(6):22-30.","journal-title":"Clin Cornerstone"},{"issue":"10169","key":"key20200731145257_B4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","unstructured":"4. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet [Internet]. 2019;393(10169):364-76. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673618321123","journal-title":"Lancet"},{"issue":"9041","key":"key20200731145257_B5","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","unstructured":"5. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-41.","journal-title":"Lancet"},{"issue":"24","key":"key20200731145257_B6","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","unstructured":"6. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the fracture intervention trial. J Am Med Assoc. 1998;280(24):2077-82.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"key20200731145257_B7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","unstructured":"7. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11(1):83-91.","journal-title":"Osteoporos Int"},{"issue":"14","key":"key20200731145257_B8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","unstructured":"8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. J Am Med Assoc. 1999;282(14):1344-52.","journal-title":"J Am Med Assoc"},{"issue":"5","key":"key20200731145257_B9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","unstructured":"9. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333-40.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20200731145257_B10","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","unstructured":"10. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-9.","journal-title":"J Bone Miner Res"},{"key":"key20200731145257_B11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis","volume":"356","author":"Black","year":"2007","unstructured":"11. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356:1809-22.","journal-title":"N Engl J Med"},{"issue":"8","key":"key20200731145257_B12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","unstructured":"12. Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-65.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20200731145257_B13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","unstructured":"13. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637-45.","journal-title":"JAMA"},{"issue":"19","key":"key20200731145257_B14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","unstructured":"14. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-41.","journal-title":"N Engl J Med"},{"issue":"7","key":"key20200731145257_B15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","unstructured":"15. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722-33.","journal-title":"JAMA"},{"key":"key20200731145257_B16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/CIA.S54614","article-title":"The epidemiology and management of postmenopausal osteoporosis: A viewpoint from Brazil","volume":"10","author":"Baccaro","year":"2015","unstructured":"16. Baccaro LF, Conde DM, Costa-Paiva L, Pinto-Neto AM. The epidemiology and management of postmenopausal osteoporosis: A viewpoint from Brazil. Clin Interv Aging. 2015;10:583-91.","journal-title":"Clin Interv Aging"},{"issue":"11","key":"key20200731145257_B17","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","unstructured":"17. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520-6.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20200731145257_B18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/14712598.2017.1280455","article-title":"Romosozumab for the treatment of osteoporosis","volume":"17","author":"Bandeira","year":"2017","unstructured":"18. Bandeira L, Lewiecki EM, Bilezikian JP. Romosozumab for the treatment of osteoporosis. Expert Opin Biol Ther [Internet]. 2017;17(2):255-63. Available from: http:\/\/dx.doi.org\/10.1080\/14712598.2017.1280455","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"key20200731145257_B19","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1210\/jc.2011-0593","article-title":"Atypical femoral fractures during prolonged use of bisphosphonates: Short-term responses to strontium ranelate and teriparatide","volume":"96","author":"Carvalho","year":"2011","unstructured":"19. Carvalho NNC, Voss LA, Almeida MOP, Salgado CL, Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: Short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011;96(9):2675-80.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20200731145257_B20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","unstructured":"20. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"key20200731145257_B21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/jbmr.3671","article-title":"Treated Osteoporosis Is Still Osteoporosis","volume":"34","author":"Lewiecki","year":"2019","unstructured":"21. Lewiecki EM, Binkley N, Bilezikian JP. Treated Osteoporosis Is Still Osteoporosis. J Bone Miner Res. 2019;34(4):605-6.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"key20200731145257_B22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research","volume":"29","author":"Shane","year":"2014","unstructured":"22. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2014;29(1):1-23.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"key20200731145257_B23","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","unstructured":"23. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27(12):2544-50.","journal-title":"J Bone Miner Res"},{"issue":"24","key":"key20200731145257_B24","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial long-term extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","unstructured":"24. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial long-term extension (FLEX): A randomized trial. JAMA. 2006;296(24):2927-38.","journal-title":"JAMA"},{"issue":"2","key":"key20200731145257_B25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","unstructured":"25. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243-54.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20200731145257_B26","article-title":"The impact of Bisphosphonate Drug Holidays on Fracture Rates","author":"Curtis","year":"2018","unstructured":"26. Curtis JR, Rui Chen, Zixu Li, Tarun Arora, Saag KG, Wright NC, et al. The impact of Bisphosphonate Drug Holidays on Fracture Rates. J Bone Miner Res. 2018;Suppl(2):2, #1006.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"key20200731145257_B27","article-title":"Bisphosphonate Use and Risk of AFF Varies by Pre-treatment BMD Level: Results from the Southern California Osteoporosis Cohort Study (SOCS)","author":"Black","year":"2018","unstructured":"27. Black DM, Geiger EJ, Li BH, Ryan DS, RM D, Annette L. Addams. Bisphosphonate Use and Risk of AFF Varies by Pre-treatment BMD Level: Results from the Southern California Osteoporosis Cohort Study (SOCS). J Bone Miner Res. 2018;Suppl(2):2, #1007.","journal-title":"J Bone Miner Res"},{"key":"key20200731145257_B28","article-title":"Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: Nationwide cohort and nested case-control study","volume":"353","author":"Abrahamsen","year":"2016","unstructured":"28. Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: Nationwide cohort and nested case-control study. BMJ. 2016;353:i3365.","journal-title":"BMJ"},{"key":"key20200731145257_B29","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate Use and Atypical Fractures of the Femoral Shaft","volume":"364","author":"Schilcher","year":"2011","unstructured":"29. J\u00f6rg Schilcher, Karl Micha\u00eblsson, Per Aspenberg. Bisphosphonate Use and Atypical Fractures of the Femoral Shaft. N Engl J Med. 2011;(364):1728-37.","journal-title":"N Engl J Med"},{"key":"key20200731145257_B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161435.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2016","volume":"22","author":"Camacho","year":"2016","unstructured":"30. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis 2016. Endocr Pract. 2016;22(Suppl 4):1-42.","journal-title":"Endocr Pract"},{"issue":"22","key":"key20200731145257_B31","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis - For whom and for how long?","volume":"366","author":"Black","year":"2012","unstructured":"31. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis - For whom and for how long? N Engl J Med. 2012;366(22):2051-3.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20200731145257_B32","article-title":"Predicting Fracture Risk During a Bisphosphonate Holiday in the FIT Long-term Extension (FLEX) Study: Comparison of a Custom Risk Tool vs FRAX","author":"Black","year":"2019","unstructured":"32. Black DM, Schwartz A, Bauer DC, Cauley J, Ensrud K, Napoli N. Predicting Fracture Risk During a Bisphosphonate Holiday in the FIT Long-term Extension (FLEX) Study: Comparison of a Custom Risk Tool vs FRAX. J Bone Miner Res. 2019;Suppl(2):31#1089.","journal-title":"J Bone Miner Res"},{"issue":"11","key":"key20200731145257_B33","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1210\/jc.2014-1193","article-title":"A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring","volume":"99","author":"McNabb","year":"2014","unstructured":"33. McNabb B, Vittinghoff E, Eastell R, Schwartz AV, Bauer DC, Ensrud K, et al. A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring. J Clin Endocrinol Metab. 2014;99(11):4094-100.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"key20200731145257_B34","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/jbmr.3420","article-title":"Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study","volume":"33","author":"Adams","year":"2018","unstructured":"34. Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, et al. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study. J Bone Miner Res. 2018;33(7):1252-9.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"key20200731145257_B35","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","article-title":"International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis","volume":"49","author":"Vasikaran","year":"2011","unstructured":"35. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011;49(8):1271-4.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"key20200731145257_B36","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0585","article-title":"Bone turnover markers: Are they clinically useful?","volume":"178","author":"Eastell","year":"2018","unstructured":"36. Eastell R, Pigott T, Gossiel F, Naylor KE, Walsh JS, Peel NFA. Bone turnover markers: Are they clinically useful? Eur J Endocrinol. 2018;178(1):R19-31.","journal-title":"Eur J Endocrinol"},{"key":"key20200731145257_B37","doi-asserted-by":"crossref","first-page":"115158","DOI":"10.1016\/j.bone.2019.115158","article-title":"The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study","volume":"131","author":"Gossiel","year":"2020","unstructured":"37. Gossiel F, Paggiosi MA, Naylor KE, McCloskey EV, Walsh J, Peel N, et al. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone [Internet]. 2020;131:115158. Available from: https:\/\/doi.org\/10.1016\/j.bone.2019.115158","journal-title":"Bone"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T18:53:16Z","timestamp":1596221596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2359-39972020005005204&lng=en&nrm=iso"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,17]]},"references-count":37,"alternative-id":["10.20945\/2359-3997000000275"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000275","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"type":"print","value":"2359-3997"},{"type":"electronic","value":"2359-4292"}],"subject":[],"published":{"date-parts":[[2020,7,17]]}}}